ReviewJournal of nanobiotechnology2025
Harnessing smart nanomaterials to reprogram neutrophil plasticity in immune modulation.
Review in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Nanomedicine and the tumor immune microenvironment in cancer immunotherapy: a bibliometric and knowledge-mapping analysis.Frontiers in oncology · 2026Pooled it
- Engineered Neutrophils in Translational Medicine: Gene Editing, Nanotechnology, and AI-Driven Clinical Breakthroughs.Advanced healthcare materials · 2026Review
- Smart Nanomaterials and Natural Biologics for Innate-Adaptive Immune Reprogramming: A Nanobiotechnology Framework for Translational Medicine.Nanomaterials (Basel, Switzerland) · 2026Review
- Cell-free DNA in precision medicine: overcoming biological barriers through integrated nanoparticle platforms for simultaneous diagnosis and therapy.Journal of nanobiotechnology · 2026Review
- Transforming Nanomaterials Development with Artificial Intelligence Techniques.Nanotechnology, science and applications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Neutrophils are the most abundant type of white blood cells in the immune system and play a complex and intricate regulatory role in disease progression. Their critical contribution to maintaining homeostasis through migration, activation, and programmed cell death is indispensable. In contrast to traditional nanocarrier-based drugs, smart nanomaterials capable of precisely targeting distinct stages of neutrophil development can dynamically regulate drug distribution in both time and space while controlling the fate of neutrophils during migration, activation, and apoptosis. This enables the realization of precise and personalized disease diagnosis and treatment. Therefore, this review introduces a state-of-the-art framework for intelligent nano-immune engineering, wherein artificial intelligence-driven nano-design, dynamic response systems, and biomimetic materials science are integrated into the spatiotemporal reprogramming of neutrophil fate. We analyze stage-specific targeting strategies that are computationally learned, biologically validated, and synthetically optimized, while highlighting their emerging applications in precision therapy. By synergistically merging materials science, immunology, and intelligent technologies, we aim to offer novel perspectives on the advancement of the burgeoning field of "intelligent nano-immune engineering" and lay a solid foundation for the development of next-generation intelligent therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.